Predictive Technology Group (Predictive Technology Group) Retained Earnings : $-156.82 Mil (As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Predictive Technology Group's retained earnings for the quarter that ended in Mar. 2021 was $-156.82 Mil.

Predictive Technology Group's quarterly retained earnings declined from Sep. 2020 ($-142.33 Mil) to Dec. 2020 ($-149.44 Mil) and declined from Dec. 2020 ($-149.44 Mil) to Mar. 2021 ($-156.82 Mil).

Predictive Technology Group's annual retained earnings declined from Jun. 2018 ($-25.81 Mil) to Jun. 2019 ($-41.10 Mil) and declined from Jun. 2019 ($-41.10 Mil) to Jun. 2020 ($-126.87 Mil).

Predictive Technology Group Retained Earnings Historical Data

The historical data trend for Predictive Technology Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group Retained Earnings Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

Retained Earnings

Get a 7-Day Free Trial

-16.84

-23.02

-25.81

-41.10

-126.87

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Retained Earnings	Get a 7-Day Free Trial															-88.67	-126.87	-142.33	-149.44	-156.82

Predictive Technology Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Predictive Technology Group (OTCPK:PRED) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.